A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice

Vaccine

Volumn 17, Issue 9-10, 1999, Pages 1239-1250

  Babai, Ilan ^a   Samira, Sarit ^a   Barenholz, Yechezkel ^a   Zakay Rones, Zichria ^a   Kedar, Eli ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cytokines; Influenza vaccine; Liposomes; Mice

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HN PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; ENCAPSULATION; FEMALE; HUMORAL IMMUNITY; INFLUENZA VIRUS A; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ANIMALS; ANTIBODY FORMATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN A; INFLUENZA A VIRUS; INFLUENZA VACCINES; INTERLEUKIN-2; LIPOSOMES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; TH1 CELLS; TH2 CELLS;

EID: 0033525805     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00347-8     Document Type: Article

References (65)

1. Ortbals D.W., Liebhaber H., Presant C.A., Van Amburg A.l., Lee J.Y. Influenza immunization of adult patients with malignant diseases. Ann Int Med. 87:1977;552-557.
2. Gross P.A., Lee H., Wolff J.A., Hall C.B., Minnefore A.B., Lazicki M.E. Influenza immunization in immunosuppressed children. J Pediatr. 92:1978;30-35.
3. Keren G., Segev S., Morag A., Zakay-Rones Z., Barzilai A., Rubinstein E. Failure of influenza vaccination in the aged. J Med Virol. 25:1988;85-89.
4. Engelhard D., Nagler A., Hardan I., Morag A., Aker M., Baciu H.et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T-cell-depleted and autologous BMT recipients. Bone Marrow Transp. 11:1993;1-5.
5. Kilbourne ED. Inactivated influenza vaccines. In: Plotkin A, Mortimer Jr, EA, editors. Vaccines. Philadelphia: Saunders, 1994. p. 565-581.
6. Evans T.G., Judd M.E., Dowell T., Poe S., Daynes R.A., Araneo B.A. The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly. Vaccine. 14:1996;1531-1537.
7. de Bruijn I.A., Remarque E.J., Beyer W.E.P., le Cessie S., Masurel N., Ligthart G.J. Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly. Vaccine. 15:1997;1323-1329.
8. Clements ML, Stephens I. New and improved vaccines against influenza. In: Levine MM, Woodrow GC, Kaper JB and Cobon GS, editors. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, 1997. p. 545-570.
9. Gupta R.K., Siber G.R. Adjuvants for human vaccines: current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
10. Edelman R. Adjuvants for the future. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, 1997. p. 173-192.
11. Alving C.R. Immunologic presentation of liposomal antigens. J Liposome Res. 3:1993;493-504.
12. Alving CR. Liposomes as adjuvants for vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, 1997. p. 207-213.
13. Pietrobon P.J. Liposome design and vaccine development. Pharm Biotechnol. 6:1995;347-361.
14. Gregoriadis G. Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods. 4:1994;210-216.
15. Gregoriadis G., Gursel I., Gursel M., McCormack B. Liposomes as immunological adjuvants and vaccine carriers. J Controlled Release. 41:1996;49-56.
16. Dong P., Ho R.J.Y. Application of liposomes in antigen presentation and cytokine delivery. J Liposome Res. 6:1996;305-323.
17. Gluck R, Cryz Jr, SJ. Immunopotentiating reconstituted influenza virosomal vaccine delivery system. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, 1997. p. 247-252.
18. Mannino RJ, Gould-Fogerite S. Antigen cochelate preparations for oval and systemic vaccination. In: Levine MM. Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, 1997. p. 229-237.
19. Kersten G.F., Crommelin D.J.A. Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta. 1241:1995;117-138.
20. O'Hagen DT. Prospects for the development of new and improved vaccines through the use of microencapsulation technology. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, 1997. p. 215-228.
21. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol. 15:1997;617-648.
22. Haynes J.R., Fuller D.H., McCabe D., Swain W.F., Widera G. Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv Drug Deliv Rev. 21:1996;3-18.
23. Gluck R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344:1994;160-163.
24. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B., Gluck R., Cryz S.J. Jr. Immunogenicity of trivalent subunit vs. virosome-formulated influenza vaccines in geriatric patients. Vaccine. 15:1997;1675-1679.
25. Powers D.C. Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mech Aging Dev. 93:1997;179-188.
26. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice vaccine. 1999;17:1223-1238.
27. Aluminum hydroxide adjuvant. In: Harlow E., Lane D., editors. Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratoy, 1988. pp. 99.
28. Kirby C., Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology. 2:1984;979-984.
29. Eckstein M., Barenholz Y., Bar L.K., Segal E. Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against candidiasis in mice. Vaccine. 15:1997;220-224.
30. Minamide L.S., Bamburg J.R. A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal Biochem. 190:1990;66-70.
31. Kedar E., Rutkowski Y., Braun E., Emanuel N., Barenholz Y. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother. 16:1994;47-59.
32. Kedar E., Palgi O., Golod G., Babai I., Barenholz Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNFα show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother. 20:1997;180-193.
33. Sever J. Application of microtechnique to viral serologic investigation. J Immunol. 88:1962;321-325.
34. Leshem B., Gotsman B., Kedar E. In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization. Cancer Immunol Immunother. 17:1984;117-123.
35. Hennet T., Zitener H.J., Frei K., Peterhans E. A Kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J Immunol. 149:1992;932-939.
36. Hackett C.J., Taylor P.M., Askonas B.A. Stimulation of cytotoxic T-cells by liposomes containing influenza virus or its components. Immunology. 49:1983;255-263.
37. Boudreault A., Tibodeau L. Mouse response to influenza immunosomes. Vaccine. 3:1985;231-234.
38. Torchillin VP, Butkhanov SA, Zazhul LA, Ageeva ON. Liposomal vaccine against influenza virus. In: Gregoriadis G, editor. Liposomes as Drug Carriers: Recent Trends and Progress. Chichester: Wiley, 1988. p. 229-232.
39. El Guink N., Kris R.M., Goodman-Snitkoff G., Small P.A. Jr., Mannino R.J. Intranasal immunization with proteoliposomes protects against influenza. Vaccine. 7:1989;147-151.
40. Gregoriadis G., Tan L., Ben-Ahmeida E.T.S., Jennings R. Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen. Vaccine. 10:1992;747-753.
41. Ben Ahmeida E.T.S., Gregoriadis G., Potter C.W., Jennings R. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine. 11:1993;1302-1309.
42. Ben Ahmeida E.T.S., Potter C.W., Gregoriadis G., Adithan C., Jennings R. IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines. J Med Microbiol. 40:1994;261-269.
43. Naruse H., Ogasawara K., Kaneda R., Hatakeyama S., Itoh T., Kida H., Miyazaki T., Good R.A., Onoe K. A potential peptide vaccine against two different strains of influenza virus at intervals of about 10 years. Proc Natl Acad Sci USA. 91:1994;9588-9592.
44. Friede M., Muller S., Briand J.P., Plaue S., Fernandes I., Frisch B., Schuber F., Van Regenmortel M.H. Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes. Vaccine. 12:1994;791-797.
45. Bullough P.A., Hughson F.M., Skehel J.J., Wiley D.C. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature. 371:1994;37-43.
46. Gluck R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine. 10:1992;915-919.
47. Rao M., Rothwell S.W., Wassef N.M., Pagano R.E., Alving C.R. Visualization of peptides derived from liposome-encapsulated proteins in the trans-Golgi area of macrophages. Immunol Lett. 59:1997;99-105.
48. Benne C.A., Harmsen M., van der Graff W., Verheul A.F., Snippe H., Kraaijeveld C.A. Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants. Vaccine. 15:1997;1039-1044.
49. Wagner D.K., Clements M.L., Reimer C.B., Snyder M., Nelson D.L., Murphy B.R. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol. 25:1987;559-562.
50. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 24:1986;157-160.
51. Mbawuike I.N., Wyde P.R., Anderson P.M. Enhancement of the protective efficacy of inactivated influenza A virus in aged mice by IL-2 liposomes. Vaccine. 8:1990;347-352.
52. Cao M., Sasaki O., Yamada A., Imanishi J. Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine. 10:1992;238-242.
53. Noria A., Rubin R.H. Cytokines as potential vaccine adjuvants. Biotherapy. 7:1994;261-269.
54. Lin R., Tarr P.E., Jones T.C. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis. 21:1995;1439-1449.
55. Heath AW. Cytokines as immunological adjuvants. In: Powell MF, Newman MJ, editors. Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995. p. 645-658.
56. Gursel M., Gregoriadis G. Immunoadjuvant action of liposomes containing interleukin-2 as a coadjuvant. Proc Int Symp Control Rel Bioact Mater. 22:1995;938-939.
57. Lachman L.B., Ozpolat B., Rao X.M. Cytokine-containing liposomes as vaccine adjuvants. Eur Cytokine Netwa. 7:1996;693-698.
58. Kedar E, Barenholz Y. Delivery of cytokines by liposomes: A means of improving their immunomodulatory and antitumor activity. In: Chouaib S, editor. The biotherapy of Cancers: from Immunotherapy to Gene Therapy. Paris: INSERM, 1998, p. 333-62.
59. Tan L., Gregoriadis G. The effect of interleukin-2 on the immunoadjuvant action of liposomes. Biochem Soc Trans. 17:1989;693-694.
60. Mc Michael A. Cytotoxic T lymphocytes specific for influenza virus. Curr Top Microbiol Immunol. 189:1994;75-91.
61. Iinuma H., Nerome K., Yoshioka Y., Okinaga K. Characteristics of cytotoxic T lymphocytes directed to influenza virus haemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine. Scand J Immunol. 41:1995;1-10.
62. Mbawuike I.N., Acuna C., Caballero D., Pham-Nguen K., Gilbert B., Petribon P., Harmon M. Reversal of age-related deficient influenza virus-specific CTL responses and IFNγ production by monophosphoryl lipid A. Cell Immunol. 173:1996;64-78.
63. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., McGhee J.R. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med. 185:1997;415-427.
64. Gursel M., Gregoriadis G. Interleukin-15 acts as an immunological coadjuvant for liposomal antigen in vivo. Immunol Lett. 55:1997;161-165.
65. Chen K., Braun S., Lyman S., Fan Y., Traycoff C.M., Wiebke E.A., Gaddy J., Sledge G., Broxmeyer H.E., Cornetta K. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57:1997;3511-3516.